Author "Kim, Jake D."

articles+ search results

16 articles+ results

1 - 16
View results as:
Number of results to display per page

1. Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination [2022]

  • Chiang, Teresa PY, Alejo, Jennifer L., Mitchell, Jonathan, Kim, Jake D., Abedon, Aura T., Karaba, Andrew H., Thomas, Letitia, Levan, Macey L., Garonzik-Wang, Jacqueline M., Avery, Robin K., Pekosz, Andrew, Clarke, William A., Warren, Daniel S., Tobian, Aaron A. R., Massie, Allan B., Segev, Dorry L., and Werbel, William A.
  • American Journal of Transplantation. September, 2022, Vol. 22 Issue 9, p2254, 7 p.

2. 6-month antibody kinetics and durability after four doses of a SARS-CoV-2 vaccine in solid organ transplant recipients [2023]

  • Mitchell, Jonathan, Chiang, Teresa PY, Alejo, Jennifer L., Kim, Jake D., Chang, Amy, Abedon, Aura T., Avery, Robin K., Tobian, Aaron A. R., Levan, Macey L., Warren, Daniel S., Garonzik-Wang, Jacqueline M., Segev, Dorry L., Massie, Allan B., and Werbel, William A.
  • Clinical Transplantation. January, 2023, Vol. 37 Issue 1, pn/a, 3 p.

3. Improved humoral immunogenicity with mRNA-1273 versus BNT162b2 as third vaccine dose among solid organ transplant recipients seronegative after two BNT162b2 doses [2022]

  • Chang, Amy, Chiang, Teresa PY., Kim, Jake D., Mitchell, Jonathan, Alejo, Jennifer L., Jefferis, Alexa A., Avery, Robin K., Tobian, Aaron A. R., Levan, Macey L., Warren, Daniel S., Garonzik-Wang, Jacqueline M., Massie, Allan B., Segev, Dorry L., and Werbel, William A.
  • Clinical Transplantation. August, 2022, Vol. 36 Issue 8, pn/a, 4 p.

4. Antibody response to a third dose of SARS-CoV-2 vaccine in heart and lung transplant recipients [2022]

  • Alejo, Jennifer L., Ruck, Jessica M., Chiang, Teresa P. Y., Abedon, Aura T., Kim, Jake D., Avery, Robin K., Tobian, Aaron A. R., Warren, Daniel S., Levan, Macey L., Massie, Allan B., Garonzik-Wang, Jacqueline M., Segev, Dorry L., and Werbel, William A.
  • Clinical Transplantation. November, 2022, Vol. 36 Issue 11, pn/a, 3 p.

5. Immunogenicity of Ad26.COV2.S prime and two subsequent doses of mRNA SARS-CoV-2 vaccines in solid organ transplant recipients: A case series [2022]

  • Chang, Amy, Mitchell, Jonathan, Alejo, Jennifer L., Chiang, Teresa P.Y., Abedon, Aura T, Kim, Jake D., Avery, Robin K., Tobian, Aaron A.R., Levan, Macey L., Warren, Daniel S., Garonzik-Wang, Jacqueline M., Massie, Allan B., Segev, Dorry L., and Werbel, William A.
  • Clinical Transplantation. September, 2022, Vol. 36 Issue 9, pn/a, 3 p.

6. 330.5: A Prediction Model for Antibody Response to Three Vaccines Against SARS-CoV-2 Among Solid Organ Transplant Recipients [2022]

  • Alejo, Jennifer, Chiang, Teresa PY, Mitchell, Jonathan, Kim, Jake D, Abedon, Aura T, Avery, Robin K, Tobian, Aaron AR, Garonzik-Wang, Jacqueline M, Warren, Daniel S, Segev, Dorry L, Werbel, William A, and Bae, Sunjae
  • Transplantation. Sep 01, 2022 106(9S Suppl 1):S263-S264

7. 230.6: Ad.26.COV2.S Versus BNT162b2 or mRNA-1273 as a Third Dose in Solid Organ Transplant Recipients Seronegative After 2-dose mRNA Vaccination [2022]

  • Chiang, Teresa Po-Yu, Alejo, Jennifer L, Mitchell, Jonathan, Kim, Jake D, Abedon, Aura T, Karaba, Andrew H, Thomas, Letitia, Levan, Macey L, Garonzik-Wang, Jacqueline M, Avery, Robin K, Pekosz, Andrew, Clarke, William A, Warren, Daniel S, Tobian, Aaron AR, Massie, Allan B, Segev, Dorry L, and Werbel, William A
  • Transplantation. Sep 01, 2022 106(9S Suppl 1):S71-S72

8. 230.1: Incidence and Severity of COVID-19 Infections Among Triple-vaccinated Solid Organ Transplant Recipients During the Omicron Variant Surge in the United States (12/25/2021-3/1/2022) [2022]

  • Alejo, Jennifer, Chiang, Teresa PY, Zeiser, Laura Bowles, Kim, Jake D, Mitchell, Jonathan, Avery, Robin K, Tobian, Aaron AR, Massie, Allan B, Werbel, William A, and Segev, Dorry L
  • Transplantation. Sep 01, 2022 106(9S Suppl 1):S67-S68

9. 210.5: Differential Immunogenicity of mRNA-1273 Versus BNT162b2 as a Third Vaccine Dose for Solid Organ Transplant Recipients Seronegative After Two BNT162b2 Doses. [2022]

  • Chang, Amy, Chiang, Teresa PY, Alejo, Jennifer L, Mitchell, Jonathan, Kim, Jake D, Abedon, Aura T, Avery, Robin K, Tobian, Aaron AR, Massie, Allan B, Levan, Macey L, Warren, Daniel S, Garonzik-Wang, Jacqueline M, Segev, Dorry L, and Werbel, William A
  • Transplantation. Sep 01, 2022 106(9S Suppl 1):S3-S3

10. Incidence and Severity of COVID-19 Among Vaccinated Solid Organ Transplant Recipients During the Omicron Wave [2022]

  • Alejo, Jennifer L., Chiang, Teresa P.Y., Bowles Zeiser, Laura, Kim, Jake D., Mitchell, Jonathan, Avery, Robin K., Tobian, Aaron A. R., Abedon, Rivka R., Levan, Macey L., Warren, Daniel S., Garonzik-Wang, Jacqueline M., Massie, Allan B., Segev, Dorry L., and Werbel, William A.
  • Transplantation. Sep 01, 2022 106(9):e413-e415

11. Six-month Antibody Kinetics and Durability After 3 Doses of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series [2022]

  • Abedon, Aura T., Alejo, Jennifer L., Kim, Jake D., Thomas, Letitia, Mitchell, Jonathan, Chiang, Teresa P. Y., Avery, Robin K., Tobian, Aaron A. R., Levan, Macey L., Warren, Daniel S., Massie, Allan B., Garonzik-Wang, Jacqueline M., Segev, Dorry L., and Werbel, William A.
  • Transplantation. 106(5):e281-e283

12. 6-mo Antibody Kinetics and Durability After 3 Doses of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series [2022]

  • Abedon, Aura T., Alejo, Jennifer L., Kim, Jake D., Thomas, Letitia, Mitchell, Jonathan, Chiang, Teresa P.Y., Avery, Robin K., Tobian, Aaron A.R., Levan, Macey L., Warren, Daniel S., Massie, Allan B., Garonzik-Wang, Jacqueline M., Segev, Dorry L., and Werbel, William A.
  • Transplantation. Jan 19, 2022

13. Patient‐reported outcomes after Tixagevimab and Cilgavimab pre‐exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk. [2023]

  • Alejo, Jennifer L., Kim, Jake D., Chiang, Teresa P.Y., Avery, Robin K., Karaba, Andrew H., Jefferis, Alexa, Warren, Daniel S., Massie, Allan B., Tobian, Aaron A.R., Segev, Dorry L., and Werbel, William A.
  • Clinical Transplantation. Jan2023, p1. 8p. 1 Illustration, 2 Charts.
Abstract
Background Methods Results Conclusions Tixagevimab and Cilgavimab (T + C) is authorized for pre‐exposure prophylaxis (PrEP) against Coronavirus Disease 2019 (COVID‐19) in solid organ transplant recipients (SOTRs), yet patient‐reported outcomes after injection are not well described. Furthermore, changes in risk tolerance after T + C PrEP have not been reported, of interest given uncertain activity against emerging Omicron sublineages.Within a national prospective observational study, SOTRs who reported receiving T + C were surveyed for 3 months to ascertain: (1) local and systemic reactogenicity, (2) severe adverse events with focus on cardiovascular and alloimmune complications, and (3) breakthrough COVID‐19, contextualized through (4) changes in attitudes regarding COVID‐19 risk and behaviors.At 7 days postinjection, the most common reactions were mild fatigue (29%), headache (20%), and pain at injection sites (18%). Severe adverse events were uncommon; over 3 months of follow‐up, 4/392 (1%) reported acute rejection and one (.3%) reported a myocardial infarction. Breakthrough COVID‐19 occurred in 9%, 16–129 days after receiving full dose (300/300 mg) T + C, including two non‐ICU hospitalizations. Most surveyed SOTRs (65%) felt T + C PrEP was likely to reduce their COVID‐19 risk, and 70% reported increased willingness to engage in social activities such as visiting friends. However, few felt safe to return to in‐person work (20%) or cease public mask‐wearing (15%).In this prospective study of patient‐reported outcomes, T + C was well tolerated with few serious events. Several COVID‐19 breakthroughs were reported, notable as most SOTRs reported changes in risk tolerance after T + C. These results aid counseling of SOTRs regarding real‐world safety and effectiveness of T + C. [ABSTRACT FROM AUTHOR]

14. Improved Antibody Response After a Fifth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series [2022]

  • Abedon, Aura T., Teles, Mayan S., Alejo, Jennifer L., Kim, Jake D., Mitchell, Jonathan, Chiang, Teresa P. Y., Avery, Robin K., Tobian, Aaron A. R., Levan, Macey L., Warren, Daniel S., Massie, Allan B., Garonzik-Wang, Jacqueline M., Segev, Dorry L., and Werbel, William A.
  • Transplantation. 106(5):e262-e263

15. This title is not available for guests. Log in to see the title and access the article.

16. Omicron BA.1 and BA.2 Neutralizing Activity Following Pre-Exposure Prophylaxis with Tixagevimab plus Cilgavimab in Vaccinated Solid Organ Transplant Recipients. [2022]

  • Karaba AH, Kim JD, Chiang TP, Alejo JL, Abedon AT, Mitchell J, Chang A, Eby Y, Johnston TS, Aytenfisu T, Hussey C, Jefferis A, Fortune N, Abedon R, Thomas L, Warren DS, Sitaras I, Pekosz A, Avery RK, Massie AB, Clarke WA, Tobian AAR, Segev DL, and Werbel WA
  • MedRxiv : the preprint server for health sciences [medRxiv] 2022 May 26. Date of Electronic Publication: 2022 May 26.
Abstract
Neutralizing antibody responses are attenuated in many solid organ transplant recipients (SOTRs) despite SARS-CoV-2 vaccination. Pre-exposure prophylaxis (PrEP) with the monoclonal antibody combination Tixagevimab and Cilgavimab (T+C) might augment immunoprotection, yet activity against Omicron sublineages in vaccinated SOTRs is unknown. Vaccinated SOTRs who received 300+300mg T+C (either single dose or two 150+150mg doses) within a prospective observational cohort submitted pre- and post-injection samples between 1/10/2022-4/4/2022. Binding antibody (anti-receptor binding domain [RBD], Roche) and surrogate neutralization (%ACE2 inhibition; ≥20% connoting neutralizing inhibition, Meso Scale Discovery) were measured against variants including Omicron sublineages BA.1 and BA.2. Data were analyzed using the Wilcoxon matched-pairs signed-rank test and McNemar's test. Among 61 participants, median (IQR) anti-RBD increased from 424 (IQR <0.8-2322.5) to 3394.5 (IQR 1403.9-7002.5) U/ml post T+C (p<0.001). The proportion demonstrating vaccine strain neutralizing inhibition increased from 46% to 100% post-T+C (p<0.001). BA.1 neutralization was low and did not increase (8% to 16% of participants post-T+C, p=0.06). In contrast, BA.2 neutralization increased from 7% to 72% of participants post-T+C (p<0.001). T+C increased anti-RBD levels, yet BA.1 neutralizing activity was minimal. Encouragingly, BA.2 neutralization was augmented and in the current variant climate T+C PrEP may serve as a useful complement to vaccination in high-risk SOTRs.

Catalog

Books, media, physical & digital resources
See catalog results

Guides

Course- and topic-based guides to collections, tools, and services.
Search ""Kim, Jake D."" in all guide pages